Selected Grants
A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants with Moderate to Severe Hidradenitis Suppurativa
Clinical TrialPrincipal Investigator · Awarded by Lilly USA, LLC · 2024 - 2028Sonoma SBT777101-02
Clinical TrialPrincipal Investigator · Awarded by Sonoma Biotherapeutics, Inc. · 2024 - 2027A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2024 - 2027UCB Hidradenitis Suppurativa - Extention
Clinical TrialPrincipal Investigator · Awarded by UCB Pharma, Inc. · 2021 - 2025Sex hormones in Hidradenitis Suppurativa
ResearchPrincipal Investigator · Awarded by Dermatology Foundation · 2020 - 2024A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants with Moderate to Severe Hidradenitis Suppurativa
Clinical TrialPrincipal Investigator · Awarded by Lilly USA, LLC · 2024 - 2028Sonoma SBT777101-02
Clinical TrialPrincipal Investigator · Awarded by Sonoma Biotherapeutics, Inc. · 2024 - 2027A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2024 - 2027UCB Hidradenitis Suppurativa - Extention
Clinical TrialPrincipal Investigator · Awarded by UCB Pharma, Inc. · 2021 - 2025Sex hormones in Hidradenitis Suppurativa
ResearchPrincipal Investigator · Awarded by Dermatology Foundation · 2020 - 2024Racial variation in Sex Steroid effects in Women with Hidradenitis Suppurativa
ResearchPrincipal Investigator · Awarded by Skin of Color Society Foundation · 2020 - 2024Duke Skin of Color Fellowship
FellowshipPrincipal Investigator · Awarded by Pfizer, Inc. · 2021 - 2023A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults with Moderate-to-Severe Hidradenitis Suppurativa
Clinical TrialPrincipal Investigator · Awarded by Lilly USA, LLC · 2021 - 2023A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa
Clinical TrialPrincipal Investigator · Awarded by UCB Pharma, Inc. · 2020 - 2023A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2020 - 2021External Relationships
- Eli Lilly & Co.
- IDEOM
- Novartis pharmaceuticals
- Skin of Color Society
- UCB Pharma
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.